PM Modi s Vaccine Diplomacy Goes For A Toss As India s Health System Crumbles
All the drum beating about Vaccine Maitri appear hollow when the government is not in a position to deliver health care to its own people. PTI Seema Guha 2021-04-22T17:23:19+05:30 PM Modi s Vaccine Diplomacy Goes For A Toss As India s Health System Crumbles outlookindia.com 2021-04-22T17:26:53+05:30
Also read
India’s second deadly wave of Covid-19 has shattered Prime Minister Narendra Modi’s carefully orchestrated vaccine diplomacy leaving several neighbouring nations high and dry, dependent on India’s generosity.
There is no way that India can honour its commitment to provide vaccines when the country is facing an unprecedented health emergency with the essential supply of oxygen, drugs, hospital beds running out.
Covishield is being produced at a much higher scale than Covaxin.
NEW DELHI: Covishield, from the Oxford/AstraZeneca stable, comprises over 90 per cent of the 12.76 crore Covid-19 vaccines administered across the country so far, according to government data on Wednesday.
Of this, 15 states and Union territories have only given Covishield, being manufactured by the Pune-based Serum Institute of India. The other vaccine being administered in India is the indigenous Covaxin from Bharat Biotech in Hyderabad.
Giving details, of the 127,605,870 Covid-19 vaccination jabs administered till now, 11,60,65,107 are of Covishield while 1,15,40,763 are of Covaxin, according to the government s CO-WIN portal.
Moreover, about 15 states and Union territories, including Goa, Chandigarh and Jammu and Kashmir, have administered only Covishield to its beneficiaries.
Synopsis
Giving details, of the 127,605,870 COVID-19 vaccination jabs administered till now, 11,60,65,107 are of Covishield while 1,15,40,763 are of Covaxin, according to the government s CO-WIN portal.
Agencies
Covishield
Covishield, from the Oxford/AstraZeneca stable, comprises over 90 per cent of the 12.76 crore COVID-19 vaccines administered across the country so far, according to government data on Wednesday. Of this, 15 states and union territories have only given Covishield, being manufactured by the Pune-based Serum Institute of India. The other vaccine being administered in India is the indigenous Covaxin from Bharat Biotech in Hyderabad.
Giving details, of the 127,605,870 COVID-19 vaccination jabs administered till now, 11,60,65,107 are of Covishield while 1,15,40,763 are of Covaxin, according to the government s CO-WIN portal.
Govt must stop panic rush for second dose of Covishield April 21, 2021, 6:30 PM IST
A journalist who has lived all over India and is now based in Bangalore
Senior citizens and those over 45 with co-morbidities are rushing to take the second dose of the Covid-19 vaccine after just four weeks of the first dose even though the Government of India had advised all states to increase the interval between doses to six to eight weeks, says a news-report by Sunitha Rao in The Times Of India dated April 17. There is, she says, an apprehension of a shortage of vaccines. She notes that “Manufacturers of Covishield say that efficacy of the vaccine is 53.2% if the second dose is taken after four weeks. This increases to 60.5% if the interval is 9 to 11 weeks. If the space between doses is 12 weeks or more, efficiency increases to 78.7%.”
Central govt okays Rs 3,000 cr credit for Serum Institute
Central govt okays Rs 3,000 cr credit for Serum Institute
Agencies / Updated: Apr 20, 2021, 06:00 IST
In a bid to boost
vaccine production amid rising
Serum Institute of India (SII) and
Bharat Biotech, it was announced on Monday. The Union finance ministry has approved sanction of Rs 3,000 crore credit for the
Serum Institute and Rs 1,500 crore to Bharat Biotech, and the credit will be disbursed at the earliest.
Earlier,
Adar Poonawalla, CEO of the Pune-based Serum Institute of India, had suggested that the company would require around Rs 3,000 crore to increase production of COVID-19 vaccines.